Entheon Biomedical Corp
CNSX:ENBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Entheon Biomedical Corp
Total Liabilities & Equity
Entheon Biomedical Corp
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Entheon Biomedical Corp
CNSX:ENBI
|
Total Liabilities & Equity
CA$401.1k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Liabilities & Equity
$1.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities & Equity
CA$84.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities & Equity
$751.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
36%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Liabilities & Equity
$236.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
58%
|
CAGR 10-Years
95%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities & Equity
CA$86.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
Entheon Biomedical Corp
Glance View
Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.
See Also
What is Entheon Biomedical Corp's Total Liabilities & Equity?
Total Liabilities & Equity
401.1k
CAD
Based on the financial report for Nov 30, 2024, Entheon Biomedical Corp's Total Liabilities & Equity amounts to 401.1k CAD.
What is Entheon Biomedical Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
-66%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Entheon Biomedical Corp have been -66% over the past three years .
